UiPath Inc. (NYSE:PATH) Shares Sold by Aigen Investment Management LP

Aigen Investment Management LP lowered its position in shares of UiPath Inc. (NYSE:PATH – Get Rating) by 92.8% in the fourth quarter, HoldingsChannel.com reports. The fund owned 16,951 shares of the healthcare company’s stock after selling 217,683 shares during the quarter. Aigen Investment Management LP’s holdings in UiPath were worth $215,000 as of its most recent filing with the SEC.

Other large investors have also added to or reduced their stakes in the company. Creative Planning boosted its position in UiPath by 7.0% in the second quarter. Creative Planning now owns 10,163 shares of the healthcare company’s stock valued at $185,000 after buying an additional 666 shares during the last quarter. Daiwa Securities Group Inc. boosted its holdings in UiPath by 27.0% in the fourth quarter. Daiwa Securities Group Inc. now owns 4,585 shares of the healthcare company’s stock valued at $58,000 after purchasing an additional 974 shares during the last quarter. Parallel Advisors LLC raised its stake in shares of UiPath by 6.0% during the 4th quarter. Parallel Advisors LLC now owns 20,082 shares of the healthcare company’s stock valued at $255,000 after buying an additional 1,131 shares during the last quarter. Amalgamated Bank lifted its holdings in shares of UiPath by 1.7% in the 3rd quarter. Amalgamated Bank now owns 69,879 shares of the healthcare company’s stock valued at $881,000 after buying an additional 1,135 shares during the period. Finally, Interchange Capital Partners LLC raised its position in UiPath by 7.9% during the third quarter. Interchange Capital Partners LLC now owns 17,212 shares of the healthcare company’s stock valued at $217,000 after acquiring an additional 1,256 shares in the last quarter. Hedge funds and other institutional investors own 56.40% of the company’s stock.

Insider Activity

In other UiPath news, CAO Hitesh Ramani sold 12,000 shares of the firm’s stock in a transaction on Friday, March 17th. The stock was sold at an average price of $17.01, for a total transaction of $204,120.00. Following the completion of the sale, the chief accounting officer now owns 407,349 shares of the company’s stock, valued at $6,929,006.49. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, CFO Ashim Gupta sold 40,000 shares of the company’s stock in a transaction that occurred on Friday, March 17th. The shares were sold at an average price of $16.96, for a total value of $678,400.00. Following the transaction, the chief financial officer now directly owns 1,319,051 shares in the company, valued at approximately $22,371,104.96. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CAO Hitesh Ramani sold 12,000 shares of the stock in a transaction that occurred on Friday, March 17th. The stock was sold at an average price of $17.01, for a total transaction of $204,120.00. Following the transaction, the chief accounting officer now directly owns 407,349 shares of the company’s stock, valued at approximately $6,929,006.49. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 92,000 shares of company stock valued at $1,529,720. 31.88% of the stock is currently owned by company insiders.

UiPath Stock Down 11.2 %

Shares of PATH opened at $14.51 on Friday. UiPath Inc. has a 52-week low of $10.40 and a 52-week high of $22.30. The stock has a fifty day simple moving average of $15.51 and a two-hundred day simple moving average of $14.38. The company has a market capitalization of $8.09 billion, a PE ratio of -33.74 and a beta of 0.69.

UiPath (NYSE:PATH – Get Rating) last released its quarterly earnings data on Wednesday, March 15th. The healthcare company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.02. UiPath had a negative net margin of 21.55% and a negative return on equity of 10.18%. The firm had revenue of $308.55 million during the quarter, compared to analysts’ expectations of $278.14 million. As a group, equities analysts anticipate that UiPath Inc. will post -0.33 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on PATH. Royal Bank of Canada lifted their target price on shares of UiPath from $17.00 to $18.00 and gave the company a “sector perform” rating in a report on Wednesday, March 29th. TD Cowen lifted their price target on UiPath from $20.00 to $22.00 and gave the company an “outperform” rating in a research note on Monday, April 3rd. BMO Capital Markets lowered their price target on UiPath from $20.00 to $18.00 in a research report on Thursday. Canaccord Genuity Group raised UiPath from a “hold” rating to a “buy” rating and raised their price objective for the company from $14.50 to $19.00 in a report on Thursday, March 16th. Finally, Wells Fargo & Company lifted their price target on shares of UiPath from $18.00 to $20.00 and gave the company an “overweight” rating in a research note on Thursday, March 16th. Eight research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, UiPath currently has an average rating of “Hold” and an average price target of $18.87.

About UiPath

(Get Rating)

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, and Japan. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.